Vanguard Global Advisers
URGN icon

Vanguard Global Advisers’s UroGen Pharma URGN Stock Holding History

Vanguard Global Advisers’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$312K Hold
8,472
– – ﹤0.01% 2310
2026
Q1 		$152K Buy
+8,472
New +$170K ﹤0.01% 2558

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Vanguard Global Advisers's URGN Position: Q2 2026 in Review

Vanguard Global Advisers held its UroGen Pharma (URGN) position steady in Q2 2026 at 8,472 shares worth $312K. The position accounts for ﹤0.01% of the portfolio, ranked #2310.

Vanguard Global Advisers first reported a position in URGN in Q1 2026 and has held it in 2 quarters since. 187 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • Vanguard Global Advisers held 8,472 shares of UroGen Pharma worth $312K as of Q2 2026.
  • Vanguard Global Advisers left its UroGen Pharma share count unchanged in Q2 2026.
  • UroGen Pharma made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2310 holding.
  • Vanguard Global Advisers first reported a position in UroGen Pharma in Q1 2026 and has held it in 2 quarters since.
  • 187 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.